Qiang Zeyuan, Wan Juan, Chen Xiangzheng, Wang Haichuan
Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine/West China School of Nursing, Sichuan University, Chengdu, China.
Transl Cancer Res. 2024 Jun 30;13(6):3156-3178. doi: 10.21037/tcr-24-837. Epub 2024 Jun 27.
Hepatocellular carcinoma (HCC) is a highly heterogeneous and aggressive tumor. In recent years, the incidence of HCC has been increasing worldwide. Despite notable advancements in treatment methodologies, the prognosis of HCC patients remains unsatisfactory. ErbB family proteins play important roles in the occurrence, progression, and metastasis of HCC, and their abnormal expression is often closely associated with poor patient prognosis. This article sought to investigate the current status and research progress of ErbB family protein targeted therapy in HCC in recent years to provide a reference for basic research and clinical treatment.
We performed a comprehensive, narrative review of the latest literature to define the current progress of ErbB family receptors in HCC in both the pre-clinical and clinical arenas.
The ErbB family belongs to the tyrosine kinase (TK) receptor family that comprises four members. These members are closely associated with proliferation, cell cycle regulation, and migration during HCC development through multiple signaling pathways. ErbB-targeted therapy has shown tremendous potential and prospects in the treatment of HCC.
Through in-depth research and the application of ErbB-targeted therapy, broader avenues will be opened for the treatment of HCC and other tumors, leading to more personalized and precise treatment approaches.
肝细胞癌（HCC）是一种高度异质性且侵袭性强的肿瘤。近年来，全球范围内HCC的发病率一直在上升。尽管治疗方法取得了显著进展，但HCC患者的预后仍不尽人意。表皮生长因子受体（ErbB）家族蛋白在HCC的发生、发展和转移中发挥着重要作用，其异常表达往往与患者预后不良密切相关。本文旨在探讨近年来ErbB家族蛋白靶向治疗在HCC中的研究现状和进展，为基础研究和临床治疗提供参考。
我们对最新文献进行了全面的叙述性综述，以确定ErbB家族受体在HCC临床前和临床领域的最新进展。
ErbB家族属于酪氨酸激酶（TK）受体家族，由四个成员组成。这些成员在HCC发展过程中通过多种信号通路与增殖、细胞周期调控和迁移密切相关。ErbB靶向治疗在HCC治疗中已显示出巨大的潜力和前景。
通过深入研究和应用ErbB靶向治疗，将为HCC和其他肿瘤的治疗开辟更广阔的途径，带来更个性化、精准的治疗方法。
